149 related articles for article (PubMed ID: 35347559)
21. Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
Kraut EH; Rhoades C; Zhang Y; Cheng H; Aimiumu J; Chen P; Lang J; Young DC; Agrawal A; Dancey J; Chan KK; Grever MR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):579-86. PubMed ID: 20490801
[TBL] [Abstract][Full Text] [Related]
22. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Jänne PA; Cohen RB; Laird AD; Macé S; Engelman JA; Ruiz-Soto R; Rockich K; Xu J; Shapiro GI; Martinez P; Felip E
J Thorac Oncol; 2014 Mar; 9(3):316-23. PubMed ID: 24496004
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
[TBL] [Abstract][Full Text] [Related]
24. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Soria JC; LoRusso P; Bahleda R; Lager J; Liu L; Jiang J; Martini JF; Macé S; Burris H
Oncologist; 2015 Mar; 20(3):245-6. PubMed ID: 25669662
[TBL] [Abstract][Full Text] [Related]
27. A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
Puglisi M; Molife LR; de Jonge MJ; Khan KH; Doorn LV; Forster MD; Blanco M; Gutierrez M; Franklin C; Busman T; Yang J; Eskens FA
Future Oncol; 2021 Jul; 17(21):2747-2758. PubMed ID: 33849298
[No Abstract] [Full Text] [Related]
28. Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Koolen SL; Witteveen PO; Jansen RS; Langenberg MH; Kronemeijer RH; Nol A; Garcia-Ribas I; Callies S; Benhadji KA; Slapak CA; Beijnen JH; Voest EE; Schellens JH
Clin Cancer Res; 2011 Sep; 17(18):6071-82. PubMed ID: 21753156
[TBL] [Abstract][Full Text] [Related]
29. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Padda SK; Reckamp KL; Koczywas M; Neal JW; Kawashima J; Kong S; Huang DB; Kowalski M; Wakelee HA
Cancer Chemother Pharmacol; 2022 Jan; 89(1):105-115. PubMed ID: 34773474
[TBL] [Abstract][Full Text] [Related]
30. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.
Raez LE; Papadopoulos K; Ricart AD; Chiorean EG; Dipaola RS; Stein MN; Rocha Lima CM; Schlesselman JJ; Tolba K; Langmuir VK; Kroll S; Jung DT; Kurtoglu M; Rosenblatt J; Lampidis TJ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):523-30. PubMed ID: 23228990
[TBL] [Abstract][Full Text] [Related]
31. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
Chiorean EG; Porter JM; Foster AE; Al Omari AS; Yoder CA; Fife KL; Strother RM; Murry DJ; Yu M; Jones DR; Sweeney CJ
Clin Cancer Res; 2008 Feb; 14(4):1131-7. PubMed ID: 18281547
[TBL] [Abstract][Full Text] [Related]
32. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
Vasey PA; Gore M; Wilson R; Rustin G; Gabra H; Guastalla JP; Lauraine EP; Paul J; Carty K; Kaye S;
Br J Cancer; 2008 Jun; 98(11):1774-80. PubMed ID: 18506181
[TBL] [Abstract][Full Text] [Related]
33. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Dy GK; Infante JR; Eckhardt SG; Novello S; Ma WW; Jones SF; Huff A; Wang Q; Suttle AB; Ottesen LH; Adjei AA; Burris HA
Invest New Drugs; 2013 Aug; 31(4):891-9. PubMed ID: 23135778
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies.
Goss GD; Jonker DJ; Laurie SA; Weberpals JI; Oza AM; Spaans JN; la Porte C; Dimitroulakos J
J Transl Med; 2016 Mar; 14():83. PubMed ID: 27036206
[TBL] [Abstract][Full Text] [Related]
35. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours.
de Jonge MJ; Dumez H; Kitzen JJ; Beuselinck B; Verweij J; Courtney R; Battista A; Brega N; Schöffski P
Eur J Cancer; 2011 Jun; 47(9):1328-35. PubMed ID: 21439816
[TBL] [Abstract][Full Text] [Related]
36. Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.
Goel S; Viteri S; Morán T; Coronado C; Dios JL; Miguel-Lillo B; Fernández-García EM; Rosell R
Invest New Drugs; 2016 Feb; 34(1):75-83. PubMed ID: 26627080
[TBL] [Abstract][Full Text] [Related]
37. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
38. Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
Hanauske AR; Cassidy J; Sastre J; Bolling C; Jones RJ; Rakhit A; Fettner S; Brennscheidt U; Feyereislova A; Díaz-Rubio E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):523-31. PubMed ID: 17255274
[TBL] [Abstract][Full Text] [Related]
39. A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.
Rosen LS; Goldman JW; Algazi AP; Turner PK; Moser B; Hu T; Wang XA; Tuttle J; Wacheck V; Wooldridge JE; Banck M
Clin Cancer Res; 2017 Apr; 23(8):1910-1919. PubMed ID: 27803065
[No Abstract] [Full Text] [Related]
40. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
Lockhart AC; Sundaram S; Sarantopoulos J; Mita MM; Wang-Gillam A; Moseley JL; Barber SL; Lane AR; Wack C; Kassalow L; Dedieu JF; Mita AC
Invest New Drugs; 2014 Dec; 32(6):1236-45. PubMed ID: 25117475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]